Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.

Jacobson PB, Goody R, Lawrence M, Mueller BK, Zhang X, Hooker BA, Pfleeger K, Ziemann A, Locke C, Barraud Q, Droescher M, Bernhard J, Popp A, Boeser P, Huang L, Mollon J, Mordashova Y, Cui YF, Savaryn JP, Grinnell C, Dreher I, Gold M, Courtine G, Mothe A, Tator CH, Guest JD

Open source

DOI: 10.1016/j.nbd.2021.105385
Published: 2021 Jul
Container: Neurobiology of disease
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.nbd.2021.105385,
  title = {Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.},
  author = {Jacobson PB and Goody R and Lawrence M and Mueller BK and Zhang X and Hooker BA and Pfleeger K and Ziemann A and Locke C and Barraud Q and Droescher M and Bernhard J and Popp A and Boeser P and Huang L and Mollon J and Mordashova Y and Cui YF and Savaryn JP and Grinnell C and Dreher I and Gold M and Courtine G and Mothe A and Tator CH and Guest JD},
  year = {2021},
  journal = {Neurobiology of disease},
  doi = {10.1016/j.nbd.2021.105385},
  url = {https://doi.org/10.1016/j.nbd.2021.105385}
}

RIS

TY  - JOUR
TI  - Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.
AU  - Jacobson PB
AU  - Goody R
AU  - Lawrence M
AU  - Mueller BK
AU  - Zhang X
AU  - Hooker BA
AU  - Pfleeger K
AU  - Ziemann A
AU  - Locke C
AU  - Barraud Q
AU  - Droescher M
AU  - Bernhard J
AU  - Popp A
AU  - Boeser P
AU  - Huang L
AU  - Mollon J
AU  - Mordashova Y
AU  - Cui YF
AU  - Savaryn JP
AU  - Grinnell C
AU  - Dreher I
AU  - Gold M
AU  - Courtine G
AU  - Mothe A
AU  - Tator CH
AU  - Guest JD
PY  - 2021
JO  - Neurobiology of disease
DO  - 10.1016/j.nbd.2021.105385
UR  - https://doi.org/10.1016/j.nbd.2021.105385
ER  -

APA

PB, J., R, G., M, L., BK, M., X, Z., BA, H., K, P., A, Z., C, L., Q, B., M, D., J, B., A, P., P, B., L, H., J, M., Y, M., YF, C., JP, S., C, G., I, D., M, G., G, C., A, M., CH, T., & JD, G. (2021). Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2021.105385

Source records

pubmed · retrieved 2026-09-27T07:01:06.443Z